NewsRoom Articles - Page 82 of 154 - PsychedelicNewsWire (PNW)

TuesdayOct 12, 2021 12:50 pm

Delic Holdings (CSE: DELC) (OTCQB: DELCF) Reports Second Quarter Financial Results; Sets Up Business Pillars for Continued Growth

Delic Holdings Corp. (the “company” or “Delic”) reported Q2 revenues of $149,290 while realizing a strong gross profit margin of 87% The company has recently broadened its business verticals through the acquisition of Homestead, a psychedelic media distributor, and Ketamine Infusion Centers LLC, one of the largest chains of ketamine clinics in the U.S. Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has recently published its second quarter results for the 2021 fiscal year. The company reported Q2 revenues of $149,290. Delic also reported second quarter gross profits…

MondayOct 11, 2021 12:45 pm

Elon Musk Acknowledges Potential of Psychedelic Substances at CodeCon

During an interview at CodeCon 21, Elon Musk stated that individuals should be open to psychedelic substances. The tech-development event was hosted by Field Trip Health’s executive chairman, Ronan Levy, who asked Musk about whether he supported the use of psychedelic substances for therapeutic purposes. Levy asked Musk about the role psychedelics could play in addressing some of the society’s destructive tendencies, with Musk replying that while most of individuals who were making laws currently were from a different era, there would be greater receptivity to the substances’ benefits as a new generation got into political power. Field Trip Health…

FridayOct 08, 2021 1:49 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources

Tryp Therapeutics recently launched a new website with updated resources to be featured on the site Over the next few weeks, the company will share key resources that will be the standout features of the new website Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring…

FridayOct 08, 2021 11:41 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions

Cybin names Dr. Amir Inamdar as chief medical officer for European operations The company appoints Dr. Geoff Varty as head of research and development Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made key additions and changes (https://ibn.fm/0GBMQ). Most recently the company has appointed two new executives and announced internal promotions to continue strengthening its leadership team. Cybin has named Dr. Amir Inamdar as chief medical…

FridayOct 08, 2021 11:20 am

Psychedelic Substances May Decrease Shame Among Individuals Who Suffered Mistreatment as Children

A new study, reported in the “Chronic Stress” journal, has found that the use of psychedelic substances is linked to decreased levels of internalized shame and PTSD symptoms in adults who underwent maltreatment as children. The author of the study, CJ Healy, who is a PhD student at the New School for Social Research, stated that while there existed various studies on the therapeutic effects of psychedelics, very few looked into the substances’ potential use in nonclinical settings. Healy explained that most individuals across the globe who were using psychedelics to heal themselves were taking the them in nonclinical settings,…

ThursdayOct 07, 2021 9:30 am

Grand Rapids City Council Approves Psychedelics Decriminalization Measure

Earlier last week, another city in the state of Michigan passed a measure that called for the decriminalization of psychedelics, including ayahuasca and psilocybin. The measure doesn’t meet activists’ expectations, however, because it doesn’t change any enforcement practices in the city. Instead, the initiative stipulates that the city commission and mayor support federal, state and local legislative efforts to decriminalize entheogenic fungi and plants as well as plant-based compounds that are classified under the Controlled Substances Act. The measure, which the city commission of Grand Rapids approved in a 5 to 2 vote, states that individuals who seek to improve…

WednesdayOct 06, 2021 1:19 pm

Former Congresswoman Backs the Use of Psilocybin in Treating Alcohol Use Disorder

Former Congresswoman Mimi Walters (R) has been proclaiming the therapeutic benefits of psychedelic substances. In a recent interview, Walters revealed that somebody close to her family had been struggling to overcome alcohol use disorder while she talked about a legislation that would legalize the possession of various psychedelics. The former Republican congresswoman, who left Congress in 2019, explained that the close family friend had been able to recover from the disorder with the help of psilocybin after participating in a study conducted at New York University. Various studies have shown that some psychedelics may be effective in treating conditions such…

TuesdayOct 05, 2021 11:00 am

What Investors Consider Before Investing in Psychedelic Startup Companies

In the last few years, venture-capital funds have played a big role in facilitating the establishment of psychedelic firms. To do this, those VC companies have had to go through many business models and pitches. Research shows that the top investors in the psychedelics industry since the beginning of last year are Neo Kuma, Palo Santo and Noetic Fund. They have injected the most capital into psychedelic startup firms. In total, the three companies deployed roughly $85 million into these startups. Today, we’ll look at some of the variables these companies took into consideration as well as the qualities they…

MondayOct 04, 2021 2:00 pm

NIDA Awards Grant for Research on Potential of Psilocybin in Treating Cigarette Addiction

The National Institute on Drug Abuse is financing research on the use of magic mushrooms in managing cigarette addiction. The top federal drug agency recently awarded the grant to researchers from the University of Alabama at Birmingham, New York University and Johns Hopkins University to investigate how psilocybin could help individuals quit smoking cigarettes. Last week, Matthew Johnson, a professor at Johns Hopkins University, revealed that the researchers had been awarded the grant, noting that he believed that it was the first grant from the federal government in more than five decades to directly study the therapeutic benefits of a…

FridayOct 01, 2021 12:15 pm

Researchers Develop Statistical Model That Can Characterize Ketamine’s Effects on the Brain

Researchers from the Massachusetts General Hospital and the Picower Institute for Learning and Memory at MIT have developed a statistical model that can characterize how ketamine affects an individual’s brain. The research, which was published in “PLOS Computational Biology,” found that ketamine produced different effects, which means that to improve patient outcomes and better understand ketamine, a ketamine-specific model was needed. This is why the researchers designed a model based on rhythm measurements from two animal subjects and nine human subjects. The model defines the characteristic states of brain activity that occur when an individual is under ketamine anesthesia. In…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000